IP Library Granted Patent US 7,825,135
Granted Patent B2
US 7,825,135 · App. 10/593,950 · Granted Nov 2, 2010

Heteroaryl piperidine glycine transporter inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,825,135
App. No.
10/593,950
Granted
Nov 2, 2010
Kind
B2
Abstract

The present invention is directed to pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl piperidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.

Claims (109)

1. A compound of formula Ic:

or a pharmaceutically acceptable salt thereof, wherein:

R 1 is selected from the group consisting of:

(1) hydrogen,

(2) C 1-3 alkyl,

(3) fluoro,

(4) —CF 3 ,

(5) -morpholinyl, and

(6) —O—C 1-3 alkyl;

R 2 is phenyl, which is substituted with R 2a , R 2b and R 2c ,

R 2a , R 2b and R 2c are independently selected from the group consisting of:

(1) hydrogen,

(2) halogen,

(3) —C 1-6 alkyl,

(4) —CF 3 ,

(5) —OCF 3 ,

(6) —OCHF 2 ,

(7) —SCF 3 ,

(8) —SCHF 2 , and

(9) —NH 2 ;

R 3 is C 1-6 alkyl, which is unsubstituted or substituted with 1-6 halogen, hydroxyl, —NR 10 R 11 , or heterocycle, which is substituted with R 2a , R 2b and R 2c ;

R 4 and R 5 are independently selected from the group consisting of:

(1) hydrogen, and

(2) C 1-6 alkyl, which is unsubstituted or substituted with halogen or hydroxyl, or R 4 and R 5 taken together form a C 3-6 cycloalkyl ring; and

R 10 and R 11 are independently selected from: (a) hydrogen, (b)—C 1-6 alkyl, which is unsubstituted or substituted with hydroxy, 1-6 fluoro or —NR 12 R 13 , where R 12 and R 13 are independently selected from hydrogen and —C 1-6 alkyl, and where R 10 and R 11 may be joined to form an azetidinyl ring, (c) —C 3-6 cycloalkyl, which is unsubstituted or substituted with hydroxy, 1-6 fluoro or —NR 12 R 13 , (d) benzyl and (e) phenyl.

2. The compound of Claim 1 wherein R 2a , R 2b and R 2c are independently selected from the group consisting of:

(1) hydrogen,

(2) fluoro,

(3) chloro,

(4) bromo,

(5) —CF 3 , and

(6) —NH 2 .

3. The compound of claim 1 wherein R 1 is hydrogen or methyl.

4. The compound of claim 1 wherein R 4 is C 1-3 alkyl and R 5 is hydrogen or C 1-3 alkyl.

5. The compound of claim 4 wherein R 4 is C 1-3 alkyl in the (S) configuration and R 5 is hydrogen.

6. The compound of claim 4 wherein R 4 is methyl and R 5 is hydrogen.

7. The compound of claim 1 wherein R 4 is methyl and R 5 is methyl.

8. The compound of claim 1 wherein R 4 is hydrogen and R 5 is hydrogen.

9. The compound of claim 1 wherein R 3 is selected from C 1-6 alkyl and C 1-6 alkyl-fluoro.

10. The compound of claim 9 wherein R 3 is —CH 2 CH 3 .

11. The compound of claim 9 wherein R 3 is —(CH 2 ) 2 CH 3 .

12. A compound which is selected from the group consisting of:

2-chloro-3,6-difluoro-N-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;

2,4-dichloro-N-{[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;

2,4-dichloro-N-{(1S)-1-[1 -(ethylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}benzamide;

2-chloro-3,6-difluoro-N-{1-methyl-1 -[1 -(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}benzamide;

2-chloro-N-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;

2,6-dichloro-N-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}-benzamide;

2-bromo-N-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;

2,4-dichloro-N-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;

2-chloro-6-fluoro-N-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;

2-amino-6-chloro-N-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;

2-fluoro-6-methoxy-N-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;

2-chloro-N-{[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;

2-fluoro-N-{[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}-6-trifluoromethyl)benzamide;

2,6-difluoro-N-{[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;

2-chloro-6-fluoro-N-{[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;

2,6-dichloro-N-{[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;

2-chloro-3,6-difluoro-N-{[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;

2-chloro-4-fluoro-N-{[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;

4-chloro-2-fluoro-N-{[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;

2,4-dichloro-N-{[4-(4-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide 2,4-dichloro-N-{[1-(methylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;

2,4-dichloro-N-{[1-(isopropylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide 2,4-dichloro-N-{[1-(ethylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;

2-chloro-6-fluoro-N-{[4-(6-morpholin-4-ylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;

2,4-dichloro-N-{[4-(6-morpholin-4-ylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;

2,4,5-trifluoro-N-{[4-(6-methoxypyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;

2,4-dichloro-5-fluoro-N-{[4-(6-methoxypyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;

N-{[1 -(ethylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}-2,4-difluorobenzamide;

2,4-dichloro-N-{1-methyl-1 -[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}benzamide;

2-chloro-3,6-difluoro-N-{1-methyl-1 -[1 -(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}benzamide;

N-{1-methyl-1 -[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}-2-(trifluoromethoxy)benzamide;

2,4-dichloro-N-{1-methyl-1 -[4-(6-methylpyridin-2-yl)-1 -(propylsulfonyl)piperidin-4-yl]ethyl}benzamide;

2-chloro-3,6-difluoro-N-{1-methyl-1 -[4-(6-methylpyridin-2-yl)-1 -(propylsulfonyl)piperidin-4-yl]ethyl}benzamide;

2,4-dichloro-N-{(1S)-1-[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}benzamide;

2-chloro-3,6-difluoro-N-{(1S)-1-[1 -(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}benzamide;

2,4-dichloro-N-{(1S)-1 -[4-(6-methylpyridin-2-yl)-1 -(propylsulfonyl)piperidin-4-yl]ethyl}benzamide;

2-chloro-3,6-difluoro-N-{(1S)-1-[4-(6-methylpyridin-2-yl)-1 -(propylsulfonyl)piperidin-4-yl]ethyl}benzamide;

2-chloro-N-{(1S)-1-[1 -(ethylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}benzamide;

2-chloro-N-{(1S)-1-[1 -(ethylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}-3 ,6-difluorobenzamide;

2-chloro-N-{(1S)-1-[1 -(ethylsulfonyl)-4-(6-methylpyridin-2-yl)piperidin-4-yl]ethyl}-3,6-difluorobenzamide;

2,4-dichloro-N-{(1S)-1-[1 -(ethylsulfonyl)-4-(6-methylpyridin-2-yl)piperidin-4-yl]ethyl}benzamide;

2,4-dichloro-N-{[4-(3-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;

2,4-dichloro-N-({1-(propylsulfonyl)-4-[6-(trifluoromethyl)pyridin-2-yl]piperidin-4-yl}methyl)benzamide;

2,4-dichloro-N-({1-(propylsulfonyl)-4-[4-(trifluoromethyl)pyridin-2-yl]piperidin-4-yl}methyl)benzamide;

2,4-dichloro-N-{[4-(3-chloropyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;

2,4-dichloro-N-{[4-(3-methoxypyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;

2-chloro-N-{[4-(3-chloropyridin-2-yl)-1 -(ethylsulfonyl)piperidin-4-yl]methyl}-3,6-difluorobenzamide;

2,4-dichloro-N-{[1-(ethylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;

2,4-dichloro-N-(1-{1 -[(3 -fluoropropyl)sulfonyl]-4-pyridin-2-ylpiperidin-4-y1}ethyl)benzamide;

2,4-dichloro-N-({1-[(3 -fluoropropyl)sulfonyl]-4-pyridin-2-ylpiperidin-4-y1}methyl)benzamide;

2,4-dichloro-N-{[1-[(3 -fluoropropyl)sulfonyl]-4-(3 -fluoropyridin-2-yl)piperidin-4-yl]methyl}benzamide;

2,4-dichloro-N-{[4-(3 -fluoropyridin-2-yl)-1 -(propylsulfonyl)piperidin-4-yl]methyl}benzamide;

2,4-dichloro-N-{1-[4-(3 -fluoropyridin-2-yl)-1 -(propylsulfonyl)piperidin-4-yl]ethyl}benzamide;

2,4-dichloro-N-{[4-(6-trifluoromethylpyridin-2-yl)-1 -(propylsulfonyl)piperidin-4-yl]methyl}benzamide;

4-bromo-2-chloro-N-{[1 -(ethylsulfonyl)-4-(3-fluoropyridin-2-yl)- piperidin-4-yl]methyl}benzamide;

2,4-dichloro-N-{1 -[1 -(ethylsulfonyl)-4-(3-fluoropyridin-2-yl)- piperidin-4-yl]ethyl}benzamide;

2-bromo-4-fluoro-N-{[1 -(ethylsulfonyl)-4-(3-fluoropyridin-2-yl)- piperidin-4-yl]methyl}benzamide;

2-chloro-3,6-difluoro-N-{[1 -(ethylsulfonyl)-4-(3 -fluoropyridin-2-yl)- piperidin-4-yl]methyl}benzamide;

2,4-dichloro-N-{[1 -(ethylsulfonyl)-4-(3 -trifluoromethylpyridin-2-yl)- piperidin-4-yl]methyl}benzamide;

2,4-dichloro-N-({1-[(3 -fluoropropyl)sulfonyl]-4-(3 -trifluoromethylpyridin-2-ylpiperidin-4-yl}methyl)benzamide;

2,4,6-trifluoro-N-{[1 -(ethylsulfonyl)-4-(3 -trifluoromethylpyridin-2-yl)- piperidin-4-yl]methyl}benzamide;

2,4-dichloro-N-{[1 -(ethylsulfonyl)-4-(3 -trifluoromethylpyridin-2-yl)- piperidin-4-yl]methyl}benzamide;

2,4-dichloro-N-{1 -[4-(3 -methylpyridin-2-yl)-1 -(propylsulfonyl)piperidin-4-1]ethyl}benzamide;

N-{[4-(3 -bromopyridin-2-yl)-1 -(propylsulfonyl)piperidin-4-yl]methyl}-2,4-dichlorobenzamide;

2,4-dichloro-N-{[4-(6-fluoropyridin-2-yl)-1 -(propylsulfonyl)piperidin-4-yl]methyl}benzamide;

2,4-dichloro-N-{[4-(6-chloropyridin-2-yl)-1 -(propylsulfonyl)piperidin-4-yl]methyl}benzamide;

2,4-dichloro-N-({1-(ethylsulfonyl)-4-[3-(trifluoromethyl)pyridin-2-yl]piperidin-4-yl}methyl)benzamide;

or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and a compound of claim 1 or a pharmaceutically acceptable salt thereof.

Assignments (16)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
CHANGE OF ADDRESS Recorded May 10, 2022
From: MERCK SHARP & DOHME (UK) LIMITED
To: MERCK SHARP & DOHME (UK) LIMITED
Reel/Frame 060110/0121 →
NUNC PRO TUNC ASSIGNMENT Recorded Aug 5, 2021
From: MERCK SHARP & DOHME LIMITED
To: MERCK SHARP & DOHME (UK) LIMITED
Reel/Frame 057089/0547 →
CHANGE OF NAME Recorded Aug 29, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028866/0511 →
MERGER Recorded Aug 27, 2012
From: MERCK SHARP & DOHME CORP.
To: SCHERING CORPORATION
Reel/Frame 028850/0515 →
CHANGE OF NAME Recorded Jan 25, 2010
From: MERCK & CO., INC.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 023837/0668 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2009
From: LEWIS, RICHARD T.
To: MERCK SHARP & DOHME LIMITED
Reel/Frame 023492/0813 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2009
From: JENNINGS, ANDREW S.
To: MERCK SHARP & DOHME LIMITED
Reel/Frame 023492/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2009
From: BLACKABY, WESLEY
To: MERCK SHARP & DOHME LIMITED
Reel/Frame 023492/0821 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2009
From: WISNOSKI, DAVID D.
To: MERCK & CO., INC.
Reel/Frame 023492/0828 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2009
From: DUGGAN, MARK E.
To: MERCK & CO., INC.
Reel/Frame 023492/0831 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2009
From: LEISTER, WILLIAM H.
To: MERCK & CO., INC.
Reel/Frame 023492/0834 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2009
From: HARTMAN, GEORGE D.; LINDSLEY, CRAIG W.; WOLKENBERG, SCOTT E.; ZHAO, ZHIJIAN; WANG, YI
To: MERCK & CO., INC.
Reel/Frame 023492/0858 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2009
From: NAYLOR, ELIZABETH
To: MERCK SHARP & DOHME LIMITED
Reel/Frame 023492/0810 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2009
From: STREET, LESLIE J.
To: MERCK SHARP & DOHME LIMITED
Reel/Frame 023492/0804 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2009
From: HALLETT, DAVID
To: MERCK SHARP & DOHME LIMITED
Reel/Frame 023492/0801 →